Table 1. Baseline Demographic and Disease Characteristics in Patients with PD-L1 TC ≥25%a.
| Durvalumab monotherapy (n = 163) | Durvalumab plus tremelimumab (n = 163) | Chemotherapy (n = 162) | |
|---|---|---|---|
| Age, median (range), y | 64.0 (32-84) | 65.0 (34-87) | 64.5 (35-85) |
| <65 y | 82 (50.3) | 77 (47.2) | 81 (50.0) |
| ≥65 y | 81 (49.7) | 86 (52.8) | 81 (50.0) |
| Sex, No. (%) | |||
| Male | 113 (69.3) | 118 (72.4) | 106 (65.4) |
| Female | 50 (30.7) | 45 (27.6) | 56 (34.6) |
| Race, No. (%) | |||
| White | 101 (62.0) | 111 (68.1) | 113 (69.8) |
| Asian | 59 (36.2) | 50 (30.7) | 47 (29.0) |
| Black | 2 (1.2) | 1 (0.6) | 1 (0.6) |
| ECOG performance status, No. (%) | |||
| 0 | 57 (35.0) | 65 (39.9) | 70 (43.2) |
| 1 | 105 (64.4) | 98 (60.1) | 91 (56.2) |
| 2b | 1 (0.6) | 0 | 0 |
| Tumor histologic subtype, No. (%) | |||
| Squamous | 52 (31.9) | 53 (32.5) | 52 (32.1) |
| Nonsquamous | 111 (68.1) | 110 (67.5) | 110 (67.9) |
| Smoking history, No. (%) | |||
| Never smoker | 24 (14.7) | 25 (15.3) | 21 (13.0) |
| Former smoker | 92 (56.4) | 96 (58.9) | 102 (63.0) |
| Current smoker | 47 (28.8) | 42 (25.8) | 39 (24.1) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small cell lung cancer; PD-L1, programmed cell death ligand 1; TC, tumor cell.
a
Primary analysis population. Data cutoff date: October 4, 2018.
b
Patients were required to have an ECOG performance status25 score of 0 or 1 during screening, but at baseline the score had worsened to 2 in 1 patient.